Free · 13,591 studies indexed

lighttherapyresearch.com is a free index of research on photobiomodulation and light therapy, gathered from the world’s journals and trial registries.

Sections
Skin & Wound Healing

Efficacy and safety of skin-adhesive low-level light therapy for overactive bladder: a Phase III study

LLLT may be clinically useful and safe for the treatment of OAB.

Excerpt from the paper’s abstract. Read the full paper for the details.

AI-generated summary

The authors report a randomized, double-blind, sham-controlled trial of a skin-adhesive light therapy device for overactive bladder, used at home three times daily for 12 weeks. Urge incontinence episodes fell more in the active-device group than in the sham group, and adverse events were similar between groups. The authors conclude the therapy may be clinically useful and safe, but the abstract gives no further detail on certainty or follow-up.

Who or what was studied
Patients with a clinical diagnosis of overactive bladder treated at two university hospitals
Limits stated in the abstract
The abstract does not state the total number of participants or the wavelength of the device, and the between-group differences were modest with wide standard deviations.

Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.

Abstract

Introduction And Hypothesis

Overactive bladder (OAB) is a common condition that remains challenging to treat. We hypothesized that skin-adhesive low-level light therapy (LLLT) would be an effective treatment for OAB caused by bladder muscle contraction. Accordingly, we aimed to evaluate the efficacy and safety of an LLLT device for the treatment of OAB.

Methods

This prospective, randomized, double-blind, placebo-controlled, multicenter trial included patients with a clinical diagnosis of OAB who were treated at either of two university hospitals. Patients were instructed to apply an LLLT device (Color DNA-WSF) or a sham device at home three times daily for 12 weeks. The primary outcome was the change in the mean daily number of urge urinary incontinence (UUI) episodes between baseline and 12 weeks. The secondary outcomes were the mean changes in incontinence, voiding, and nocturia episodes from baseline and the likelihood of achieving a > 50% reduction in UUI and incontinence episodes after 12 weeks. All patients completed the Overactive Bladder Symptom Score (OABSS), Urogenital Distress Inventory-6 (UDI-6), and Impact Urinary Incontinence-7 (IIQ-7) questionnaires. Safety parameters included treatment-emergent adverse events.

Results

Compared with those in the sham group, the numbers of UUI and urinary incontinence episodes in the LLLT group were significantly decreased at week 12 (UUI, (-1.0 ± 1.7 vs. -0.4 ± 2.5, P = 0.003; urinary incontinence, -1.1 ± 1.9 vs. -0.5 ± 2.9, P=0.002). Furthermore, the OABSS, UDI-6, and IIQ-7 scores at week 12 tended to be better in the LLLT group than in the sham group. The incidence of device-related treatment-emergent adverse events was similar between groups.

Conclusions

LLLT may be clinically useful and safe for the treatment of OAB.

Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.

How to read a trial: what to check before relying on this kind of research.

Terms in this paper: Low-level laser therapy, Sham, Placebo-controlled, Primary outcome, Sham device. Each links to its definition in the glossary.

A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.

Related studies